HOMA-IR

Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023  

Retrieved on: 
Monday, November 6, 2023
Adiponectin, Arm, University, American Association for the Study of Liver Diseases, Hepatology, Diabetes, II, Liver, C-reactive protein, CAP, Genotype, Lipid metabolism, Fibrosis, Metabolic syndrome, PNPLA3, Inflammation, Type 2 diabetes, HOMA-IR, Euronext Paris, Scan (company), Steatosis, NASH, Risk, Insulin, T2D, Abstract, Histology, Serum, MM, Insulin resistance, Adipose tissue, Patient, Fatty liver disease, Metabolism, Glucose, Medical device, Medical imaging, Pharmaceutical industry

The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.

Key Points: 
  • The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.
  • Two additional scientific abstracts from the NATIVE Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH have been selected  for presentation.
  • The two abstracts show:
    the correlation between the increase of adiponectin under lanifibranor and the improvement of histological and serum markers of NASH severity both in terms of activity and fibrosis.
  • the improvement of liver histology and markers of cardiometabolic health in patients with NASH treated with lanifibranor, independent of PNPLA3 genotype.

Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)

Retrieved on: 
Monday, July 17, 2023
Fatty liver disease, HOMA-IR, Corcept Therapeutics, CORT, Liver, Metabolism, NASH, MD, Patient, LDL, Liver disease, Dietary supplement, Medical imaging

These patients also experienced improvements in key metabolic and lipid measures such as HOMA-IR, serum triglycerides and LDL.

Key Points: 
  • These patients also experienced improvements in key metabolic and lipid measures such as HOMA-IR, serum triglycerides and LDL.
  • “Miricorilant is highly active in the liver with a unique mechanism of action and holds great promise for the treatment of NASH,” said Naim Alkhouri, MD, FAASLD, Chief Medical Officer of Arizona Liver Health.
  • “The combination of liver fat reduction, improvement in metabolic and lipid measures and low adverse event rate is compelling.
  • Miricorilant has the potential to be a potent solution for the large patient population with NASH.”

Poxel Announces Positive Histology Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, a Novel, Proprietary Deuterium-Stabilized R-stereoisomer of Pioglitazone

Retrieved on: 
Wednesday, September 21, 2022
Research, Diabetes, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Oncology, Fatty liver disease, Probability, Fibrosis, Safety, Histology, FDA, Diabetes, TZD, HOMA-IR, Biomarker, ALT, ELF, QUICKI, Patient, Type 2, Lists of diseases, CEO, Pharmacology, Â, Medicine, QD, Pioglitazone, NAS, Pharmaceutical industry, Medical imaging, Health insurance, Aluminium, Glycated hemoglobin, MD, T2D, Euronext

PXL065 is a novel, proprietary deuterium-stabilized R-stereoisomer of pioglitazone which has reduced PPAR activity, but retains non-genomic thiazolidinedione (TZD) actions.

Key Points: 
  • PXL065 is a novel, proprietary deuterium-stabilized R-stereoisomer of pioglitazone which has reduced PPAR activity, but retains non-genomic thiazolidinedione (TZD) actions.
  • Pioglitazones positive effects in 6 independent prior trials where NASH patients were assessed via liver biopsy propelled the study of PXL065 in patients with NASH and fibrosis.
  • Based on pioglitazones proven efficacy in NASH, PXL065 could become a key product for the treatment of NASH, alone and in combination with other treatment modalities.
  • For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1).

Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis

Retrieved on: 
Monday, June 27, 2022
GGT, PNPLA3, Hepatocellular carcinoma, NASH, Patient, ALT, HOMA-IR, C-peptide, Glycated hemoglobin, HIV disease progression rates, Trial of the century, FGF21, GLOBE, Fatty liver disease, COVID-19, Fibrosis, Company, Adiponectin, Disease, Metabolism, U.S. Securities and Exchange Commission, Poster, SAN, Risk, AST, Liver injury, Lists of diseases, Security (finance), Clinical trial, Private Securities Litigation Reform Act, EFX, Histology, F4, SEC, Safety, Therapy, Data collection, Medical imaging, Pharmaceutical industry, Åkerö

The data was presented at the 2022 International Liver Congress in a poster titled Efruxifermin treatment improved histopathology and non-invasive markers of liver injury and fibrogenesis in NASH patients across PNPLA3 genotypes: a post hoc analysis of the Ph2a BALANCED study (Poster SAT-114).

Key Points: 
  • The data was presented at the 2022 International Liver Congress in a poster titled Efruxifermin treatment improved histopathology and non-invasive markers of liver injury and fibrogenesis in NASH patients across PNPLA3 genotypes: a post hoc analysis of the Ph2a BALANCED study (Poster SAT-114).
  • Genetic variants in the PNPLA3 gene have been shown to significantly increase risk of NASH-related disease progression and fibrosis severity.
  • Carriers of the I148M variant, which is prevalent among NASH patients, have a greater-than-threefold increased risk of NASH fibrosis and are at increased risk for progressing to end-stage liver disease, including hepatocellular carcinoma.
  • The data presented at the 2022 International Liver Congress show that EFX treatment improved histopathology and noninvasive markers of liver injury across PNPLA3 genotypes, including in patients carrying the I148M variant.

L-Nutra Reports on First-of-Its Kind Study Showing That Fasting Nutrition Program Improves Metabolic Control and Slows Diabetic Kidney Disease in Type 2 Diabetes Patients

Retrieved on: 
Tuesday, June 21, 2022
Nutrition, Microalbuminuria, Journal, FMD, Safety, Technology, Human, CEO, Type 2 diabetes, Metabolism, Urine, Mediterranean diet, Program, Health, Volunteering, Harvard University, Kidney disease, Diabetic nephropathy, Joslin Diabetes Center, Endocrine Society, Insulin resistance, Patient, University Hospital Heidelberg, Longevity, Fasting, Diabetes, GLOBE, HOMA-IR, Pharmaceutical industry

Diabetic kidney disease is the leading cause of end-stage kidney complication in people with diabetes.

Key Points: 
  • Diabetic kidney disease is the leading cause of end-stage kidney complication in people with diabetes.
  • The investigators explored for the first time in a randomized controlled design the clinical impact of FMD in type 2 diabetes patients.
  • They showed that FMD is safe and well tolerated when accompanied by intensive diabetes care.
  • The study recruited 40 volunteers with type 2 diabetes who had protein in their urine (a sign of kidney disease).

New Study Shows Improvements in Alzheimer's Patients

Retrieved on: 
Thursday, September 30, 2021
Adoption, Clinical trial, Dementia, Recode, Exercise, Meditation, Risk, Multimedia, Cognition, Data, Fasting, 2017 Facebook live streaming incident, Biomarker, AD, MCI, Death, Blood, Reversal, List of Facebook features, Terminal illness, SCI, Diet, Research, Maintenance, HOMA-IR, Medical device, Pharmaceutical industry, Dietary supplement

These results offer hope that the era of Alzheimer's as a terminal illness is coming to a close.

Key Points: